Program
aramchol
Its studies are mostly in Fatty Liver · Gallstones · Non-alcoholic Fatty Liver Disease · Hypercholesterolemia, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galmed Pharmaceuticals | 71 open or running | phase 2since Nov 12, 2014 | Nov 12, 2014 | none ahead |
| Galmed Medical Reserch | 20 open or running | phase 2since Feb 17, 2010 | Oct 19, 2008 | none ahead |
| Galmed Research and Development | 10 open or running | phase 2since Oct 23, 2014 | Oct 23, 2014 | none ahead |
Also a collaborator on its studies: quotient-sciences, sharp, clinintel, itamar-medical-israel, one-way-liver-owl, transperfect, clinical-reference-laboratory, alderley-analytical-ltd and wcct-global.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 19, 2008First study: phase 1 study in HypercholesterolemiaNew to Galmed Medical ReserchGalmed Medical Reserch · NCT00776841 · 41 enrolled · Israel
- Feb 17, 2010Phase 2 study in Non-alcoholic Fatty Liver DiseaseGalmed Medical Reserch · NCT01094158 · 60 enrolled · Israel
- Oct 23, 2014Galmed Research and Development's first study: phase 2 study in Fatty LiverNew to Galmed Research and DevelopmentGalmed Research and Development · NCT02279524 · 247 enrolled · United States, Chile, France and more
- Nov 12, 2014Galmed Pharmaceuticals's first study: phase 2 study in GallstonesNew to Galmed PharmaceuticalsGalmed Pharmaceuticals · NCT02325492 · 10 enrolled · Israel
- Jan 18, 2015Phase 1 study in Healthy VolunteersGalmed Pharmaceuticals · NCT02374437 · 66 enrolled
- Jun 7, 2016Phase 1 study in Healthy VolunteersGalmed Pharmaceuticals · NCT02803996 · 64 enrolled · United States
- Nov 22, 20182 phase 1 studies in HealthyGalmed Pharmaceuticals · NCT03760848, NCT03774173
- Apr 24, 2023Phase 1 study in NASHGalmed Pharmaceuticals · NCT05874336 · 6 enrolled · United Kingdom
- Nov 14, 2025Phase 1 study in HealthyGalmed Pharmaceuticals · NCT07251712 · 32 planned · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07251712Healthy · United Kingdom | 1 | Recruiting | Galmed Pharmaceuticals | Apr 15, 2026 | 32 |
| NCT05874336NASH · United Kingdom | 1 | Completed | Galmed Pharmaceuticals | Aug 11, 2020 | 6 |
| NCT03774173Healthy · United Kingdom | 1 | Completed | Galmed Pharmaceuticals | Feb 3, 2019 | 16 |
| NCT03760848Healthy · United Kingdom | 1 | Completed | Galmed Pharmaceuticals | Feb 2, 2019 | 15 |
| NCT02803996Healthy Volunteers · United States | 1 | Completed | Galmed Pharmaceuticals | Sep 2016 | 64 |
| NCT02374437Healthy Volunteers | 1 | Completed | Galmed Pharmaceuticals | Dec 2014 | 66 |
| NCT02325492Gallstones · Israel | 2 | Terminated | Galmed Pharmaceuticals | Oct 2015 | 10 |
| NCT02279524Fatty Liver · United States, Chile, France and more | 2 | Completed | Galmed Research and Development | May 22, 2018 | 247 |
| NCT01094158Non-alcoholic Fatty Liver Disease · Israel | 2 | Completed | Galmed Medical Reserch | Nov 2011 | 60 |
| NCT00776841Hypercholesterolemia · Israel | 1 | Completed | Galmed Medical Reserch | Sep 2009 | 41 |
How it is read
Names in the registry
- “Aramchol”, 13 entries
Conditions, from the studies’ own filings
- Fatty Liver, 1 study
- Gallstones, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
- Hypercholesterolemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.